Federico P. O.
- Country
- Spain
- Department
- Servicio de Medicina Interna
Research Overview
- A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants
- Phase 3 Randomized Double‑Blind Study of Doravirine/Islatravir Versus Bictegravir Combination Therapy in Treatment‑Naïve HIV‑1 Infection
Data & Insights
Has run more than one trial at 20 of 29 partner sites.
Specializations
HIV Treatment Innovation
Specializes in evaluating novel therapeutic approaches for HIV-1 infection, particularly focusing on antiretroviral treatment strategies for treatment-naïve patients.
- Two-drug versus three-drug regimens
- Antiretroviral therapy optimization
- Treatment efficacy assessment
Investigates comparative effectiveness of various antiretroviral combinations, including integrase inhibitors and protease inhibitors.
Advanced HIV Management
Conducts research on treatment strategies for late-presenting HIV patients, examining optimal therapeutic approaches for advanced disease stages.
- Late presenter treatment protocols
- Advanced HIV care optimization
- Treatment response monitoring
Evaluates safety and tolerability profiles of different antiretroviral combinations in various patient populations.
Clinical Outcomes Research
Focuses on measuring antiretroviral activity and therapeutic outcomes through comprehensive clinical assessments.
- Viral load suppression
- Long-term treatment efficacy
- Safety profile evaluation
Specializes in comparative analysis of treatment regimens through extended follow-up periods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.